Upcoming Events
Priavoid nimmt vom 13. bis 16. Juni an der Bio International Convention in San Diego teil. Unser CEO Philipp Buerling und unser Mitgründer Dieter Willbold freuen sich darauf Sie zu treffen! Wir haben auch einen Stand am German Pavillion.
ADD TRANSLATION Priavoid GmbH is a drug discovery company that was founded in September 2017 as a spin-off from Heinrich Heine University Düsseldorf and Forschungszentrum Jülich. The company develops novel all-d-peptide drug candidates for the treatment of neurodegenerative diseases such as Alzheimer’s, Parkinson’s, ALS, tauopathies and Huntington’s disease. The most advanced candidate is PRI-002 for Alzheimer’s disease. All drug candidates are designed for their anti-prionic mode of action. CEO: Philipp Bürling, Supervisory Board: Prof. Dr. Dr. h.c. Detlev Riesner (Chairman), Nobel Laureate Prof. Dr. Stanley Prusiner, Prof. Dr. Dieter Willbold.